系统综述与Meta分析:肝细胞癌肝移植术后以西罗莫司或依维莫司为基础的免疫抑制方案
该系统综述与Meta分析比较了肝移植术后早期启用mTOR抑制剂(西罗莫司或依维莫司)方案与钙调神经磷酸酶抑制剂方案对肝细胞癌(HCC)患者复发与生存的影响。结果显示,mTOR抑制剂组1年与3年无复发生存率显著升高、5年无复发生存率未见统计学显著升高,1年、3年、5年总生存率均改善,复发率降低,急性排斥反应未见显著增加。作者认为mTOR抑制剂方案可能更优,未来研究应明确其在高危与低危人群中的效果。
要点
- 与钙调神经磷酸酶抑制剂相比,mTOR抑制剂组1年无复发生存率RR 1.09(95%CI 1.01-1.18)、3年RR 1.1(95%CI 1.01-1.21)显著升高。
- mTOR抑制剂组复发率更低(RR 0.67,95%CI 0.56-0.82),急性排斥反应未见显著增加(RR 1.1,95%CI 0.94-1.28)。
- mTOR抑制剂组1年、3年、5年总生存率均改善,5年无复发生存率未见统计学显著升高(RR 1.15,95%CI 0.99-1.35)。
核心结论
- 以mTOR抑制剂为基础的免疫抑制方案在HCC肝移植患者中可能更优,至少3年内改善无复发生存并降低复发率,且急性排斥反应率未见显著增加。
- 未来研究应明确该方案在高危与低危队列中的效果。
研究设计与样本
- 系统综述与Meta分析,纳入报告移植后早期(<6个月)启用mTOR抑制剂方案对HCC肝移植患者生存或肿瘤复发影响的观察性或干预性研究,对照为钙调神经磷酸酶抑制剂方案。
主要发现
- 与钙调神经磷酸酶抑制剂对照相比,mTOR抑制剂组1年无复发生存率RR 1.09(95%CI 1.01-1.18)、3年RR 1.1(95%CI 1.01-1.21)显著升高,5年RR 1.15(95%CI 0.99-1.35)未见统计学显著升高。
- mTOR抑制剂组1年总生存率RR 1.07(95%CI 1.02-1.12)、3年RR 1.1(95%CI 1.02-1.19)、5年RR 1.18(95%CI 1.08-1.29)均改善。
- mTOR抑制剂组复发率更低(RR 0.67,95%CI 0.56-0.82)。
- mTOR抑制剂组急性排斥反应未见显著增加(RR 1.1,95%CI 0.94-1.28)。
关键数值与推荐
- 纳入标准为报告移植后早期(<6个月)启用mTOR抑制剂方案对HCC肝移植患者生存或肿瘤复发影响的观察性或干预性研究,对照为钙调神经磷酸酶抑制剂方案。
临床怎么用
- 作者认为,以mTOR抑制剂为基础的免疫抑制方案在HCC肝移植患者中可能更优。
局限性
- 未来研究应明确该方案在高危与低危队列中的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Calcineurin-inhibitor immunosuppressants (tacrolimus and ciclosporin) have been associated with an exposure-related increase in tumour recurrence following liver transplantation for hepatocellular carcinoma (HCC). Conversely, mechanistic target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) have been suggested to reduce recurrence rates and improve survival in this patient group. AIM: To clarify the potential benefit of mTOR-inhibitors in HCC transplant patients by comparing recurrence and survival outcomes with calcineurin-inhibitor-based immunosuppression. METHODS: A systematic review and meta-analysis was performed. The inclusion criteria were observational or interventional studies reporting the effect of early-initiated (<6 months post-transplant) mTOR-inhibitor-based immunosuppression on survival or tumour recurrence in patients transplanted with HCC, compared to a control of calcineurin-inhibitor-based therapy. RESULTS: Meta-analysis demonstrated that compared with calcineurin-inhibitor controls, recurrence-free-survival was significantly increased with mTOR-inhibitor-based therapy at 1-year (Risk-Ratio (RR): 1.09, 95% CI: 1.01-1.18) and 3-years (RR: 1.1, 95% CI: 1.01-1.21) post-transplant, with a nonsignificant increase at 5-years (RR: 1.15, 95% CI: 0.99-1.35). Overall survival was improved at 1-year (RR: 1.07, 95% CI: 1.02-1.12), 3-years (RR: 1.1, 95% CI: 1.02-1.19), and 5-years (RR: 1.18, 95% CI: 1.08-1.29). Recurrence-rate was lower in the mTOR-inhibitor arm (RR: 0.67, 95% CI: 0.56-0.82), with no significant increase in acute rejection (RR: 1.1, 95% CI: 0.94-1.28). CONCLUSIONS: mTOR-inhibitor-based immunosuppression may be a preferable option in patients transplanted with HCC. It improves recurrence-free-survival over at least three years and reduces the recurrence rate compared with standard calcineurin-inhibitor-based therapy, with no significant increase in the rate of acute rejection. Future research should clarify the effect in higher vs lower risk cohorts.
引用
- Grigg SE, Sarri GL, Gow PJ, et al. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2019. PMID: 30989721. doi:10.1111/apt.15253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。